The C-reactive protein-albumin-lymphocyte (CALLY) index is a useful predictor of postoperative complications in patients with a colonic stent for obstructive colorectal cancer: a Japanese multicenter study.

CALLY index Colon cancer Colonic stent

Journal

Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360

Informations de publication

Date de publication:
23 Aug 2024
Historique:
received: 02 06 2024
accepted: 03 08 2024
medline: 23 8 2024
pubmed: 23 8 2024
entrez: 23 8 2024
Statut: aheadofprint

Résumé

The C-reactive protein-albumin-lymphocyte (CALLY) index is a novel score that offers a good reflection of nutritional status, inflammatory response, and immune system status. The CALLY index is reported to correlate with the prognosis of various carcinomas. The purpose of the present study was to investigate the association between the CALLY index and the short-term prognosis of obstructive colorectal cancer managed with a colonic stent. The subjects of this retrospective study were 263 patients who underwent colorectal resection after colonic stenting for obstructive colorectal cancer between 2016 and 2023. Patients were classified into a group with a low CALLY index (CALLY-L group, n = 85) and a group with a high (CALLY-H group, n = 178) CALLY index. The CALLY-L group had greater blood loss (53 mL vs 20 mL, p = 0.002) and higher poor performance status (PS3; 20% vs 10.1%, p = 0.033), open surgery (21.2% vs 7.3%, p = 0.001), distant metastases (41.2% vs 20.8%, p = 0.01), and postoperative complications (30.6% vs. 18.5%, p = 0.039) than the CALLY-H group. Multivariate analysis identified a prolonged operative time (odds ratio 1.983, 95% confidence interval 1.013-3.881; p = 0.045), greater blood loss (odds ratio 2.572, 95% confidence interval 1.291-5.129; p = 0.007) and a low CALLY index (odds ratio 1.961, 95% confidence interval 1.013-3.795; p = 0.045) as independent predictors of complications. The CALLY index may be a useful predictor of postoperative complications of obstructive colorectal cancer.

Identifiants

pubmed: 39177756
doi: 10.1007/s00595-024-02924-9
pii: 10.1007/s00595-024-02924-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.

Références

Suh JW, Oh HK, Lee J, Yang IJ, Ahn HM, Kim DW, et al. Safety of early surgery after self-expandable metallic stenting for obstructive left-sided colorectal cancer. Surg Endosc. 2023;37(5):3873–83.
doi: 10.1007/s00464-023-09891-1 pubmed: 36717427
Kim MH, Kang SI, Lee J, Oh HK, Ahn S, Kim DW, et al. Oncologic safety of laparoscopic surgery after metallic stent insertion for obstructive left-sided colorectal cancer: a multicenter comparative study. Surg Endosc. 2022;36(1):385–95.
doi: 10.1007/s00464-021-08293-5 pubmed: 33492504
Ramphal W, Boeding JRE, Gobardhan PD, Rutten HJT, de Winter L, Crolla R, et al. Oncologic outcome and recurrence rate following anastomotic leakage after curative resection for colorectal cancer. Surg Oncol. 2018;27(4):730–6.
doi: 10.1016/j.suronc.2018.10.003 pubmed: 30449500
Matsumoto Y, Tsujimoto H, Ono S, Shinomiya N, Miyazaki H, Hiraki S, et al. Abdominal infection suppresses the number and activity of intrahepatic natural killer cells and promotes tumor growth in a murine liver metastasis model. Ann Surg Oncol. 2016;23(Suppl 2):S257–65.
doi: 10.1245/s10434-015-4466-7 pubmed: 25752891
Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer. 2010;46(6):1049–55.
doi: 10.1016/j.ejca.2010.01.020 pubmed: 20138505
Peng J, Zhang R, Zhao Y, Wu X, Chen G, Wan D, et al. Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer. Chin J Cancer. 2017;36(1):96.
doi: 10.1186/s40880-017-0260-1 pubmed: 29268783 pmcid: 5740941
Moyes LH, Leitch EF, McKee RF, Anderson JH, Horgan PG, McMillan DC. Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2009;100(8):1236–9.
doi: 10.1038/sj.bjc.6604997 pubmed: 19319134 pmcid: 2676538
Tokunaga R, Sakamoto Y, Nakagawa S, Miyamoto Y, Yoshida N, Oki E, et al. Prognostic nutritional index predicts severe complications, recurrence, and poor prognosis in patients with colorectal cancer undergoing primary tumor resection. Dis Colon Rectum. 2015;58(11):1048–57.
doi: 10.1097/DCR.0000000000000458 pubmed: 26445177
Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K. Clinical significance of the c-reactive protein to albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol. 2016;23(3):900–7.
doi: 10.1245/s10434-015-4948-7 pubmed: 26530445
Ying HQ, Deng QW, He BS, Pan YQ, Wang F, Sun HL, et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol (Northwood, London, England). 2014;31(12):305.
doi: 10.1007/s12032-014-0305-0
Petrelli F, Barni S, Coinu A, Bertocchi P, Borgonovo K, Cabiddu M, et al. The modified glasgow prognostic score and survival in colorectal cancer: a pooled analysis of the literature. Rev Recent Clin Trials. 2015;10(2):135–41.
doi: 10.2174/1574887110666150317121413 pubmed: 25778832
Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, et al. Immunonutritive scoring for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: evaluation of the CALLY Index. Cancers. 2021;13(19):5018.
doi: 10.3390/cancers13195018 pubmed: 34638502 pmcid: 8508385
Takeda Y, Sugano H, Okamoto A, Nakano T, Shimoyama Y, Takada N, et al. Prognostic usefulness of the C-reactive protein-albumin-lymphocyte (CALLY) index as a novel biomarker in patients undergoing colorectal cancer surgery. Asian J Surg. 2024;47:3492.
doi: 10.1016/j.asjsur.2024.03.054 pubmed: 38538400
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
doi: 10.1097/01.sla.0000133083.54934.ae pubmed: 15273542 pmcid: 1360123
Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hirakawa K. Prognostic significance of the preoperative ratio of C-reactive protein to albumin in patients with colorectal cancer. Anticancer Res. 2016;36(3):995–1001.
pubmed: 26976989
Liu X, Sun X, Liu J, Kong P, Chen S, Zhan Y, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol. 2015;8(4):339–45.
doi: 10.1016/j.tranon.2015.06.006 pubmed: 26310380 pmcid: 4562973
Kinoshita A, Onoda H, Takano K, Imai N, Saeki C, Fushiya N, et al. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol (Northwood, London, England). 2012;29(4):2800–8.
doi: 10.1007/s12032-012-0220-1
Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol. 2000;23(3):263–6.
doi: 10.1097/00000421-200006000-00011 pubmed: 10857890
De Magistris L, Paquette B, Orry D, Facy O, Di Giacomo G, Rat P, et al. Preoperative inflammation increases the risk of infection after elective colorectal surgery: results from a prospective cohort. Int J Colorect Dis. 2016;31(9):1611–7.
doi: 10.1007/s00384-016-2620-8
Zhou J, Hiki N, Mine S, Kumagai K, Ida S, Jiang X, et al. Role of prealbumin as a powerful and simple index for predicting postoperative complications after gastric cancer surgery. Ann Surg Oncol. 2017;24(2):510–7.
doi: 10.1245/s10434-016-5548-x pubmed: 27638673
Cao X, Zhao G, Yu T, An Q, Yang H, Xiao G. Preoperative prognostic nutritional index correlates with severe complications and poor survival in patients with colorectal cancer undergoing curative laparoscopic surgery: a retrospective study in a single Chinese institution. Nutr Cancer. 2017;69(3):454–63.
doi: 10.1080/01635581.2017.1285038 pubmed: 28287320
Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15(6):362–74.
doi: 10.1038/nri3834 pubmed: 26008591
Fukushima N, Masuda T, Tsuboi K, Takahashi K, Yuda M, Fujisaki M, et al. Prognostic significance of the preoperative C-reactive protein-albumin-lymphocyte (CALLY) index on outcomes after gastrectomy for gastric cancer. Surg Today. 2024;54:943.
doi: 10.1007/s00595-024-02813-1 pubmed: 38491233
Zhuang J, Wang S, Wang Y, Wu Y, Hu R. Prognostic value of CRP-albumin-lymphocyte (CALLY) Index in patients undergoing surgery for breast cancer. Int J Gen Med. 2024;17:997–1005.
doi: 10.2147/IJGM.S447201 pubmed: 38505146 pmcid: 10949993
Tsai YT, Ko CA, Chen HC, Hsu CM, Lai CH, Lee YC, et al. Prognostic value of CRP-albumin-lymphocyte (CALLY) Index in patients undergoing surgery for oral cavity cancer. J Cancer. 2022;13(10):3000–12.
doi: 10.7150/jca.74930 pubmed: 36046647 pmcid: 9414026
Wang W, Gu J, Liu Y, Liu X, Jiang L, Wu C, et al. Pre-treatment CRP-Albumin-Lymphocyte Index (CALLY Index) as a prognostic biomarker of survival in patients with epithelial ovarian cancer. Cancer Manag Res. 2022;14:2803–12.
doi: 10.2147/CMAR.S359968 pubmed: 36160036 pmcid: 9504533
Mutlucan UO, Bedel C, Selvi F, Zortuk Ö, Türk C, Korkut M. The effect of indicators of CALLY index on survival in glioblastoma. Ir J Med Sci. 2024;193:2029.
doi: 10.1007/s11845-024-03666-w pubmed: 38561591
Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, et al. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. Br J Cancer. 2015;112(7):1175–82.
doi: 10.1038/bjc.2015.62 pubmed: 25756396 pmcid: 4385956

Auteurs

Toshio Shiraishi (T)

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Takashi Nonaka (T)

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Tetsuro Tominaga (T)

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. tetsuro.tominaga@nagasaki-u.ac.jp.

Yuma Takamura (Y)

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Kaido Oishi (K)

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Shintaro Hashimoto (S)

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Keisuke Noda (K)

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Rika Ono (R)

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Makoto Hisanaga (M)

Department of Surgery, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki, 857-8511, Japan.

Hiroaki Takeshita (H)

Department of Surgery, National Hospital Organization Nagasaki Medical Center, 2-1001-1 Kubara, Omura, Nagasaki, 856-8562, Japan.

Mitsutoshi Ishii (M)

Department of Surgery, Isahaya General Hospital, 24-1 Eisyohigashi, Isahaya, Nagasaki, 854-8501, Japan.

Shosaburo Oyama (S)

Department of Surgery, Ureshino Medical Center, 4279-3 Ureshino, Ureshino, Saga, 843-0393, Japan.

Kazuhide Ishimaru (K)

Department of Surgery, Saiseikai Nagasaki Hospital, 2-5-1 Katafuchi, Nagasaki, Nagasaki, 850-0003, Japan.

Masaki Kunizaki (M)

Department of Surgery, Sasebo Chuo Hospital, 15 Yamato, Sasebo, Nagasaki, 857-1195, Japan.

Terumitsu Sawai (T)

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Keitaro Matsumoto (K)

Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Classifications MeSH